Blockers of Renin-Angiotensin-Aldosterone System in the Treatment of Arterial Hypertension: Classics Versus the Modern

被引：0

作者：

Kanorsky, S. G. ^{[1
]}

机构：

[1] Kuban State Med Univ, Krasnodar 350063, Russia

来源：

KARDIOLOGIYA | 2013年 / 53卷 / 10期

关键词：

arterial hypertension; angiotensin converting enzyme inhibitors; angiotensin II receptor blockers; direct renin inhibitor; CONVERTING-ENZYME-INHIBITORS; PAROXYSMAL ATRIAL-FIBRILLATION; II RECEPTOR BLOCKERS; END-POINT REDUCTION; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; HIGH-RISK; LOSARTAN INTERVENTION; CARDIOVASCULAR EVENTS; FIXED COMBINATION;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

According to results of large clinical studies angiotensin II receptor blockers (ARB) and aliskiren do not lower risk of cardiovascular complications and mortality in wide spectrum of clinical conditions and are able to worsen renal outcomes. It is expedient to prefer inhibitors of angiotensin converting enzyme in particular perindopril over ARB in the treatment of patients with arterial hypertension taking into consideration differences in effect on mortality. Fixed perindopril/indapamide combination provides achievement of target arterial pressure in many patients with uncontrolled hypertension, has good tolerability, is metabolically neutral, and possesses high organoprotective properties.

引用

页码：89 / 95

页数：7

共 56 条

[1]

Agodoa L, 2007, J HYPERTENS, V25, P951

[2]

[Anonymous], 2010, SISTEMNYE GIPERTENZI, V3, P5

[3]

[Anonymous], 2013, EUR HEART J, V34, P1023, DOI 10.1093/ eurheartj/ ehp363

[4]

[Anonymous], 2009, EUR HEART J, V30, P2461

[5] Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? [J].

Athyros, Vasilios G. ;

Mikhailidis, Dimitri P. ;

Kakafika, Anna I. ;

Tziomalos, Konstantinos ;

Karagiannis, Asterios .

EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (05) :529-535

[6] Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials [J].

Bangalore, Sripal ;

Kumar, Sunil ;

Wetterslev, Jorn ;

Messerli, Franz H. .

BMJ-BRITISH MEDICAL JOURNAL, 2011, 342

[7] Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [J].

Barnett, AH ;

Bain, SC ;

Bouter, P ;

Karlberg, B ;

Madsbad, S ;

Jervell, J ;

Mustonen, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (19) :1952-1961

[8] Treatment of hypertension in patients 80 years of age or older [J].

Beckett, Nigel S. ;

Peters, Ruth ;

Fletcher, Astrid E. ;

Staessen, Jan A. ;

Liu, Lisheng ;

Dumitrascu, Dan ;

Stoyanovsky, Vassil ;

Antikainen, Riitta L. ;

Nikitin, Yuri ;

Anderson, Craig ;

Belhani, Alli ;

Forette, Francoise ;

Rajkumar, Chakravarthi ;

Thijs, Lutgarde ;

Banya, Winston ;

Bulpitt, Christopher J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (18) :1887-1898

[9] Results of the pilot study for the Hypertension in the Very Elderly Trial [J].

Bulpitt, CJ ;

Beckett, NS ;

Cooke, J ;

Dumitrascu, DL ;

Gil-Extremera, B ;

Nachev, C ;

Nunes, M ;

Peters, R ;

Staessen, JA ;

Thijs, L .

JOURNAL OF HYPERTENSION, 2003, 21 (12) :2409-2417

[10] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

← 1 2 3 4 5 6 →